Peer-influenced content. Sources you trust. No registration required. This is HCN.

Trending Topics:
DIET & NUTRITION PATIENT EDUCATION OBESITY/WEIGHT MANAGEMENT EXERCISE/TRAINING LEGAL MATTERS GUIDELINES/RECOMMENDATIONS

Articles related to SKIN CANCER

Cosibelimab Safe, Clinically Active in Patients With mCSCC

In Study CK-301-101, the primary efficacy endpoint was objective response rate (complete + partial response, by independent central review), which was 47% (n = 15) in 32 metastatic cutaneous squamous cell carcinoma (mCSCC) patients evaluable for response, including three complete responses and 12 partial responses. The results from the study were presented at the ESMO Congress.

Dermatology September 28th 2020

Tags: SKIN CANCER SQUAMOUS CELL CARCINOMA

Topics

Sources

American Journal of Clinical Pathology (AJCP)
American Nurse Journal (ANJ)
Anesthesiology News
Annals of Internal Medicine
British Medical Journal (The BMJ)
Cancer Therapy Advisor
Cardiology Advisor
Cleveland Clinic Journal of Medicine (CCJM)
Clinical Advisor
Conexiant
Consultant360
Cureus
Dermatology Advisor
Endocrinology Advisor
Gastroenterology Advisor
GoodRx for Healthcare Professionals
Healthgrades for Professionals
Hematology Advisor
JNP: The Journal for Nurse Practitioners
Journal of Invasive Cardiology (JIC)
Journal of the American College of Cardiology (JACC)
Journal of the National Cancer Institute (JNCI)
Mayo Clinic
MD Newsline
MDLinx
MedCentral
Medical News Today (MNT)
Medical Professionals Reference (MPR)
Neurology Advisor
Oncology News Central (ONC)
Ophthalmology Advisor
Pharmacy Practice News
Physician’s Weekly
Practical Neurology
Psychiatrist.com
Psychiatry Advisor
ReachMD
Renal & Urology News
The American Journal of Nursing (AJN)
UCLA Health
WebMD
Women’s Healthcare
The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form